

Adalimumab**Section**

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.

Indications

Psoriasis of unspecified type

Benzoyl peroxide**Section**

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 5%
- Local > Topical > Lotion: 5%

Indications

Acne

Calcipotriol**Section**

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 50 µg per mL (0.005%)
- Local > Topical > Lotion: 50 µg per mL (0.005%)
- Local > Topical > Ointment: 50 µg per mL (0.005%)

Indications

Psoriasis of unspecified type

Calcitriol**Section**

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [calcipotriol](#) for

Psoriasis of unspecified type

Certolizumab pegol**Section**

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Coal tar

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 5%

Indications

Psoriasis of unspecified type

Etanercept

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Fluorouracil

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Ointment: 5%

Indications

Plantar warts

Infliximab

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

Methotrexate

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)

Indications

Psoriasis of unspecified type

Podophyllotoxin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [podophyllum resin](#) for

Plantar warts

Therapeutic equivalent to [podophyllum resin](#) for

Anogenital warts

Podophyllum resin

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 10 to 25%

Indications

Plantar warts

Anogenital warts

Salicylic acid

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Solution: 5%

Indications

Seborrhoeic dermatitis

Psoriasis of unspecified type

Ichthyoses

Tacalcitol

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Indications

Therapeutic equivalent to [calcipotriol](#) for

Psoriasis of unspecified type

Urea

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Local > Topical > Cream: 10%; 5%
- Local > Topical > Ointment: 10%; 5%

Indications

Xerosis cutis or asteatosis

Ustekinumab

Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen

Indications

Psoriasis of unspecified type